Terms ending in 2033
Every in-force patent on Beiersdorf AG's record whose computed term ends in 2033, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US D808,264 | Bottle Cap In force · High confidence | Beiersdorf AG | In force | High confidence | |
| US D808,268 | Bottle In force · High confidence | Beiersdorf AG | In force | High confidence | |
| US 9,533,963 | Alkylamidothiazoles, Cosmetic or Dermatological Preparations Containing Said Alkylamidothiazoles, and Use Thereof to Combat or Prevent Undesired Pigmentation of the Skin In force · High confidence | Beiersdorf AG | In force | High confidence | |
| US D813,670 | Bottle Cap In force · High confidence | Beiersdorf AG | In force | High confidence | |
| US D814,299 | Bottle Cap In force · High confidence | Beiersdorf AG | In force | High confidence | |
| US 9,402,801 | Active Ingredient Combinations of Magnolia Bark Extract and Hyaluronic Acid and the Cosmetic And/Or Dermatological Use Thereof In force · High confidence | Beiersdorf AG | In force | High confidence | |
| US D822,486 | Bottle Cap In force · High confidence | Beiersdorf AG | In force | High confidence | |
| US D822,489 | Bottle In force · Medium confidence | Beiersdorf AG | In force | Medium confidence | |
| US 10,179,094 | Foaming Skincare Formulations In force · High confidence | Beiersdorf AG | In force | High confidence | |
| US 10,736,825 | Foaming Skincare Formulations In force · Medium confidence | Beiersdorf AG | In force | Medium confidence |
10 of 10 patents shown. Soonest term end first, then patent number.
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.